Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$186 Mln
Revenue (TTM)
$89 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.6
Face value
--
Shares outstanding
45,283,700
CFO
$-438.70 Mln
EBITDA
$-509.13 Mln
Net Profit
$-450.82 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Y-mAbs Therapeutics (YMAB)
| -46.7 | -11.1 | -32.7 | -64.1 | -24.1 | -36.1 | -- |
|
BSE Sensex*
| 3.8 | 3.4 | 6.9 | 9.7 | 15.4 | 21.9 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Y-mAbs Therapeutics (YMAB)
| 14.7 | 39.8 | -69.9 | -67.3 | 58.4 | 53.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Y-mAbs Therapeutics (YMAB)
|
4.2 | 185.7 | 88.7 | -28.2 | -27.4 | -31 | -- | 2.1 |
| 49.3 | 7,705.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.2 | 3.8 | |
| 101.2 | 6,567.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.2 | |
| 141.4 | 6,923.8 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 56.9 | 10,643.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.4 | |
| 44.7 | 12,380.9 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.7 | 5.8 | |
| 53.3 | 6,410.0 | 1,084.3 | 485.4 | 57.0 | 103.8 | 13.8 | 13.3 | |
| 306.0 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 26.4 | 9,614.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 122.8 | 11,976.8 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41 | 4.7 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal... antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. Address: 202 Carnegie Center, Princeton, NJ, United States, 08540 Read more
Founder, Chief Business Officer & Vice Chairman
Mr. Thomas Gad
Founder, Chief Business Officer & Vice Chairman
Mr. Thomas Gad
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Y-mAbs Therapeutics Inc (YMAB) stood at $ 203 Mln as on 31-Mar-25
The share price of Y-mAbs Therapeutics Inc (YMAB) is $4.17 (NASDAQ) as of 19-May-2025 16:00 EDT. Y-mAbs Therapeutics Inc (YMAB) has given a return of -24.05% in the last 3 years.
Y-mAbs Therapeutics Inc (YMAB) has a market capitalisation of $ 186 Mln as on 19-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Y-mAbs Therapeutics Inc (YMAB) is 2.08 times as on 19-May-2025, a 5% discount to its peers’ median range of 2.19 times.
Since, TTM earnings of Y-mAbs Therapeutics Inc (YMAB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Y-mAbs Therapeutics Inc (YMAB) and enter the required number of quantities and click on buy to purchase the shares of Y-mAbs Therapeutics Inc (YMAB).
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. Address: 202 Carnegie Center, Princeton, NJ, United States, 08540
The CEO & director of Mr. Thomas Gad. is Y-mAbs Therapeutics Inc (YMAB), and CFO & Sr. VP is Mr. Thomas Gad.
There is no promoter pledging in Y-mAbs Therapeutics Inc (YMAB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Y-mAbs Therapeutics Inc. (YMAB) | Ratios |
|---|---|
|
Return on equity(%)
|
-31.04
|
|
Operating margin(%)
|
-27.4
|
|
Net Margin(%)
|
-31.84
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Y-mAbs Therapeutics Inc (YMAB) was $0 Mln.
$0.07
(
